MarketPeel
Insider Trading Intelligence
PT

Praveen Tyle

KPRX
DIRECTOR · KIORA PHARMACEUTICALS INC · CIK 0001296936
FILING MIX · LIFETIME74%/26%
BUYS
26
SELLS
9
TOTAL VALUE
$148.4K
COMPANIES
3
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
183,661
AVG SELL PX
$6.01
TRADE KIND
SHOWING 35 / 35
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Praveen Tyle, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-9.41%+0.21%-9.62%-9.62%
14d1+0.00%-12.38%-1.35%-11.03%-11.03%
30d1+0.00%-10.40%+0.32%-10.72%-10.72%
60d1+0.00%-14.11%+4.78%-18.89%-18.89%
90d1+0.00%-20.30%+5.42%-25.72%-25.72%
180d1+0.00%-10.40%+9.65%-20.05%-20.05%
1y1+0.00%-33.91%+15.41%-49.33%-49.33%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KPRX · 40,000 shares · as of Jun 10, 2026
010,00020,00030,00040,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 26 buys / 9 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
40,00040,000Jun 10, 2026Jun 11, 2026View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
30,00030,000Apr 1, 2025Apr 2, 2025View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASE
5,000$3.96$19.8K5,014Aug 19, 2024Aug 19, 2024View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,7781,778Jul 1, 2024Jul 3, 2024View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
35,00035,000Feb 29, 2024Mar 4, 2024View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
14,11020,001Nov 6, 2023Nov 6, 2023View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
5,0005,000Sep 29, 2023Oct 3, 2023View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
1,472,6921,472,692Aug 25, 2023Aug 29, 2023View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
8,0008,000Mar 3, 2023Mar 8, 2023View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
250,000250,000Jan 5, 2023Jan 5, 2023View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
250,000250,000Jan 5, 2023Jan 9, 2023View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
5,0005,000Feb 1, 2022Feb 3, 2022View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
25,000275,000Sep 14, 2021Sep 16, 2021View →
SKYE
SKYE BIOSCIENCE, INC.
PURCHASEGRANT
Stock grant
250,000250,000Jul 22, 2021Jul 26, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
28,690137,351Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
2,99072,334Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
28,69057,380Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
9,72782,061Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
26,60026,600Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
2,9900Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
9,7270Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
16,560$7.19$119.1K120,791Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
26,600108,661Feb 28, 2021Mar 2, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
32,10032,100Feb 11, 2021Feb 16, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
96,31096,310Feb 11, 2021Feb 16, 2021View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
4,844$1.96$9.5K69,344Apr 22, 2020Apr 24, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
19,89374,188Apr 22, 2020Apr 24, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
9,72627,695Feb 28, 2020Mar 3, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
2,9902,990Feb 28, 2020Mar 3, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
9,7269,727Feb 28, 2020Mar 3, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
2,99017,969Feb 28, 2020Mar 3, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
SALE
EVP, R&D
26,60053,200Feb 28, 2020Mar 3, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASE
EVP, R&D
26,60054,295Feb 28, 2020Mar 3, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
86,07086,070Feb 6, 2020Feb 10, 2020View →
LXRX
LEXICON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
258,210258,210Feb 6, 2020Feb 10, 2020View →
Other insiders · KPRX
Loading peer insiders…
About this filer
CIK 0001296936
ROLE
Director
PRIMARY
KPRX
COMPANIES
3
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001296936DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback